文献速递疼痛医学

椎体基底神经消融治疗慢性下腰痛的12个月随机多中心研究结果

Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 12-month results.
PubMed 文献 · Reg Anesth Pain Med · 2021-05-24

这项前瞻性随机对照试验在23个美国中心比较椎体基底神经(BVN)消融与标准治疗(SC)对慢性下腰痛的效果。3个月时BVN组在ODI和VAS改善上显著优于SC组,12个月时BVN组ODI平均降低25.7±18.5分、VAS降低3.8±2.7 cm,64%患者疼痛缓解≥50%,29%无痛。

要点

  • 12个月时BVN组ODI降低25.7±18.5分,VAS降低3.8±2.7 cm(均P<0.001)。
  • BVN组29%患者无痛,64%患者疼痛缓解≥50%,阿片类药物使用比例无变化。

核心结论

  • BVN消融对椎体源性慢性下腰痛患者的疼痛和功能改善显著优于标准治疗,且效果持续至12个月。

研究设计与样本

  • 前瞻性、开放标签、1:1随机对照试验,在美国23个中心纳入140例患者,BVN消融组66例,标准治疗组74例,随访至12个月。

主要发现

  • 12个月时BVN组ODI平均降低25.7±18.5分(P<0.001),VAS降低3.8±2.7 cm(P<0.001),64%患者达到≥50%疼痛缓解,29%无痛。
  • 原SC组中92%患者交叉接受BVN消融后,ODI平均降低25.9±15.5分(P<0.001)。
  • 两组阿片类药物使用比例均无显著变化(P=0.56)。

临床怎么用

  • 对于伴有Modic改变的椎体源性慢性下腰痛患者,可考虑BVN消融以改善疼痛和功能。

局限性

  • 本研究为开放标签设计,可能存在偏倚;原SC组交叉后随访仅6个月,长期数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vertebral endplates, innervated by the basivertebral nerve (BVN), are a source of chronic low back pain correlated with Modic changes. A randomized trial comparing BVN ablation to standard care (SC) recently reported results of an interim analysis. Here, we report the results of the full randomized trial, including the 3-month and 6-month between-arm comparisons, 12-month treatment arm results, and 6-month outcomes of BVN ablation in the former SC arm. METHODS: Prospective, open label, 1:1 randomized controlled trial of BVN ablation versus SC in 23 US sites with follow-up at 6 weeks, 3, 6, 9, and 12 months. SC patients were re-baselined and followed up for 6 months post BVN ablation. The primary endpoint was the between-arm comparison of mean Oswestry Disability Index (ODI) change from baseline. Secondary endpoints were Visual Analog Scale (VAS), Short Form (SF-36), EuroQual Group 5 Dimension 5-Level Quality of Life (EQ-5D-5L), responder rates, and rates of continued opioid use. RESULTS: 140 were randomized. Results from BVN ablation (n=66) were superior to SC (n=74) at 3 months for the primary endpoint (mean ODI reduction, difference between arms of -20.3 (CI -25.9 to -14.7 points; p<0.001)), VAS pain improvement (difference of -2.5 cm between arms (CI -3.37 to -1.64, p<0.001)) and quality of life outcomes. At 12 months, basivertebral ablation demonstrated a 25.7±18.5 point reduction in mean ODI (p<0.001), and a 3.8±2.7 cm VAS reduction (p<0.001) from baseline, with 64% demonstrating ≥50% reduction and 29% pain free. Similarly, the former SC patients who elected BVN ablation (92%) demonstrated a 25.9±15.5 point mean ODI reduction (p<0.001) from baseline. The proportion of opioid use did not change in either group (p=0.56). DISCUSSION/CONCLUSION: BVN ablation demonstrates significant improvements in pain and function over SC, with treatment results sustained through 12 months in patients with chronic low back pain of vertebrogenic origin.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Smuck M, Khalil J, Barrette K, et al. Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 12-month results. Reg Anesth Pain Med. 2021. PMID: 34031220. doi:10.1136/rapm-2020-102259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。